ArticleBMC ophthalmology2025
Long-term follow-up of retinal amyloid angiopathy in a large Chinese family with hereditary amyloid transthyretin.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundRetinal amyloid angiopathy (RAA) is an ocular manifestation of hereditary amyloid transthyretin (hATTR). We aimed to investigate the characteristics of disease progression of RAA in patients with ATTR Gly83Arg amyloidosis and evaluate the effect of RAA on vision.
methodsWe observed the clinical records of 131 individuals from a seven-generation Chinese family. In this family, 18 symptomatic patients were our followers. And the follow-up was 61.6 ± 47.5 months (range, 1-164; median, 48 months). RAA was diagnosed after vitrectomies based on fundus fluorescein angiography (FFA). Best-corrected visual acuity (BCVA), intraocular pressure, fundus examination outcomes, and FFA outcomes at each follow-up visit were the indicators we focused on.
resultsThe prevalence of RAA was 88.9% (32/36 eyes). Of 32 eyes diagnosed with RAA, neovascular glaucoma, choroidal hemorrhage, and tractional retinal detachment as complications associated with RAA were detected in 13 (40.6%). Of the 36 eyes evaluated, 14 (39%) had a final BCVA below 20/70. RAA and these complications associated with RAA were main causes of low vision.
conclusionsComplications associated with RAA become the most serious ocular manifestations in the patients with ATTR Gly83Arg amyloidosis. Vitrectomy is not sufficient to guarantee hATTR patients good visual function. Based on FFA results, RAA in ATTR Gly83Arg amyloidosis can be divided into three stages. Early screening and treatment for RAA is imperative before clinical stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.